Pioneering gene therapy patients stay on track, boosting Spark’s hemophilia B program – Endpoints News
Endpoints News |
Pioneering gene therapy patients stay on track, boosting Spark’s hemophilia B program
Endpoints News After rattling investors with early signs of an immune reaction in a couple of cases as well as an unexpected infusion for a suspected knee bleed, Spark Therapeutics $ONCE says that its early Phase I/II study for its hemophilia B gene therapy is … |
|
Glioblastoma ‘ecosystem’ redefined for more effective immunotherapy trials
EurekAlert (press release) A research team has revealed the intrinsic gene expression patterns of glioblastoma (GBM) tumors, insights that could drive more effective treatments for GBM, the most common and deadly malignant primary brain tumors in adults. Jackson Laboratory (JAX) … |
|
Safety issues for Novartis CAR–T therapy main focus of FDA
BioPharma Dive The Food and Drug Administration plans to ask an independent panel of experts to focus their attention on the safety profile of Novartis’ experimental CAR–T therapy tisagenlecleucel when they meet to review the leukemia treatment at a public meeting … |
|
J&J drops stem cell partner Capricor
BioPharma Dive In a move resulting in an almost 10% dive of the smaller company’s share price, Johnson & Johnson has dumped its stem cell partner Capricor Therapeutics, deciding not to exercise its option for Capricor’s lead allogeneic cell-based product candidate … |
Scientific American |
Scientists Recreated an Extinct Virus
Scientific American But some scientists fear that it could be revived through what’s known as synthetic biology — the ability to make a virus by putting together by the recipe outlined in its genetic code. The horsepox virus the Canadian team created is not a threat to … |
STAT |
What to watch for as Novartis heads to the FDA with a novel cancer therapy
STAT Novartis’ therapy, called CTL019, is a customized treatment made by harvesting patients’ white blood cells and rewiring them to home in on tumors. It’s the first so-called CAR–T therapy to come before the FDA, leading a pack of novel treatments that … Before Key Meeting, FDA Stresses Risks of Novartis CAR–T Cancer TherapyXconomy Safety issues for Novartis CAR–T therapy main focus of FDABioPharma Dive FDA panel to focus on safety of Novartis gene therapy drugReuters |